Drug
Camrelizumab Plus Chemotherapy
Camrelizumab Plus Chemotherapy: highest development phase Phase 3, developed by Jiangsu Hengrui Medicine. 1 trial record tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Jiangsu Hengrui Medicine
Trials
| Drug | Phase | Indication |
|---|---|---|
| Camrelizumab Plus Chemotherapy NCT04613674 | Phase 3 | Triple Negative Breast Cancer |
Latest
No recent events.
Follow Camrelizumab Plus Chemotherapy on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.